此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy

2021年8月16日 更新者:Stanford University

Phase I Pilot Study Evaluating Vaginal Dilator Use and Toxicity Following Vaginal Brachytherapy

This randomized, pilot phase I trial studies whether phone or email reminders increases vaginal dilator use in patients with endometrial, cervical, or vaginal cancers after they undergo brachytherapy. Brachytherapy is a type of internal radiation which uses radioactive material placed directly into or near a tumor to kill tumor cells. A reminder program may help increase use of vaginal dilators and decrease long-term side effects following brachytherapy.

研究概览

详细说明

PRIMARY OBJECTIVES:

I. Evaluate whether vaginal dilator adherence is improved with additional reminder phone calls and/or email reminder survey.

SECONDARY OBJECTIVES:

I. Evaluate whether there are differences in the length of vaginal canal between the non-intervention and intervention groups. Evaluate rates of gynecologic, urinary, and gastrointestinal toxicity.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: Patients receive no additional reminders.

ARM II: Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.

ARM III: Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.

After completion of study, patients are followed up at 10-14 weeks, 5-7 months, 8-10 months, 11-13 months, 15-17 months, 19-21 months, and 23-25 months post treatment.

研究类型

介入性

注册 (实际的)

72

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Stanford、California、美国、94305
        • Stanford University, School of Medicine

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Patients with gynecologic cancer who are undergoing vaginal brachytherapy as part of their treatment
  • Patients cannot have previously received pelvic external beam radiation or brachytherapy. Patients may be enrolled while undergoing vaginal brachytherapy radiation treatment.
  • Patients should have a life expectancy of at least 1 year
  • No Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status requirements
  • No organ and marrow function requirements
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients who have received prior pelvic external beam radiation or brachytherapy will be excluded
  • No restrictions regarding use of other investigational agents
  • No exclusion requirements due to co-morbid disease or intercurrent illness
  • No investigational agent, so no exclusion requirements regarding history of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational agent or device
  • No exclusion criteria relating to concomitant medications
  • No exclusion criteria for pregnant or nursing patients from participating in this study (Of note, pregnant patients will not be treated with vaginal brachytherapy, a requirement for enrolling on this study)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
无干预:Arm I (no intervention)
Patients receive no additional reminders.
实验性的:Arm II (email survey)
Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.
Receive reminder email survey
Receive reminder email survey
实验性的:Arm III (email surveys and phone calls)
Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.
Receive reminder email survey
Receive reminder email survey
Receive reminder phone call

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Vaginal dilator adherence, measured by the average number of times per week patient uses a form of vaginal dilation
大体时间:Up to 25 months after completing radiation
The vaginal dilator adherence measurements will analyzed in repeated measures model with treatment as a fixed effect and time as a within subject effect. The overall mean of vaginal dilator adherence among the 3 groups will also be measured and compared. The interaction between treatment and time will also be tested to see if the behavior over time is different depending on which treatment arm the patient is in.
Up to 25 months after completing radiation

次要结果测量

结果测量
措施说明
大体时间
Vaginal canal length
大体时间:Up to 25 months after completing radiation
The vaginal canal length will be measured using an extra small dilator and it will be calculated in centimeters. The vaginal canal length measurements will be analyzed in a repeated measures model with treatment as a fixed effect and time as a within subject effect. The interaction between treatment and time will also be tested to see if the behavior over time is different depending on which treatment arm the patient is in.
Up to 25 months after completing radiation
Incidence of adverse events (AE), reported by type and grade using the Common Terminology Criteria for Adverse Events version 4.03
大体时间:Up to 30 days after the last dose of study treatment
The adverse events will be tabulated by type and grade at each follow up. The total number of AE's as well as the number of AE's in each category: gynecologic, urinary and gastrointestinal will tabulated. The test of proportion will be done per category of AE. Since it is possible that the rates will be low, an exact test will be used to compare the rates.
Up to 30 days after the last dose of study treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Elizabeth Kidd、Stanford University Hospitals and Clinics

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2014年9月1日

初级完成 (实际的)

2019年1月1日

研究完成 (实际的)

2020年10月23日

研究注册日期

首次提交

2014年2月6日

首先提交符合 QC 标准的

2014年2月6日

首次发布 (估计)

2014年2月10日

研究记录更新

最后更新发布 (实际的)

2021年8月17日

上次提交的符合 QC 标准的更新

2021年8月16日

最后验证

2021年8月1日

更多信息

与本研究相关的术语

其他研究编号

  • IRB-29074
  • NCI-2013-02400 (注册表标识符:CTRP (Clinical Trial Reporting Program))
  • GYN0005 (其他标识符:OnCore)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅